{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:50:42Z","timestamp":1791946242453,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10454-2","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:02:49Z","timestamp":1729659769000},"page":"177-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Changing the paradigm in heart failure: shifting from treatment to prevention"],"prefix":"10.1007","volume":"30","author":[{"given":"Alex J.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Girouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankeet S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"8","key":"10454_CR1","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI et al (2024) 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation 149(8):e347\u2013e913. https:\/\/doi.org\/10.1161\/CIR.0000000000001209","journal-title":"Circulation"},{"issue":"18","key":"10454_CR2","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ehj.2004.06.038","volume":"25","author":"GS Bleumink","year":"2004","unstructured":"Bleumink GS, Knetsch AM, Sturkenboom MC et al (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25(18):1614\u20131619. https:\/\/doi.org\/10.1016\/j.ehj.2004.06.038","journal-title":"Eur Heart J"},{"issue":"4 Suppl A","key":"10454_CR3","doi-asserted-by":"publisher","first-page":"6A","DOI":"10.1016\/0735-1097(93)90455-a","volume":"22","author":"KK Ho","year":"1993","unstructured":"Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 Suppl A):6A-13A. https:\/\/doi.org\/10.1016\/0735-1097(93)90455-a","journal-title":"J Am Coll Cardiol"},{"key":"10454_CR4","doi-asserted-by":"publisher","unstructured":"Nichols GA, Qiao Q, D\u00e9ruaz-Luyet A, Kraus BJ (2023) The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction. Int J Cardiol Heart Vasc 47:101182. Published 2023 Feb 14. https:\/\/doi.org\/10.1016\/0735-1097(93)90455-a","DOI":"10.1016\/0735-1097(93)90455-a"},{"issue":"1","key":"10454_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","volume":"126","author":"BA Steinberg","year":"2012","unstructured":"Steinberg BA, Zhao X, Heidenreich PA et al (2012) Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126(1):65\u201375. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.080770","journal-title":"Circulation"},{"issue":"8","key":"10454_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","volume":"6","author":"CW Tsao","year":"2018","unstructured":"Tsao CW, Lyass A, Enserro D et al (2018) temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6(8):678\u2013685. https:\/\/doi.org\/10.1016\/j.jchf.2018.03.006","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10454_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.amjmed.2009.04.022","volume":"122","author":"SM Dunlay","year":"2009","unstructured":"Dunlay SM, Weston SA, Jacobsen SJ, Roger VL (2009) Risk factors for heart failure: a population-based case-control study. Am J Med 122(11):1023\u20131028. https:\/\/doi.org\/10.1016\/j.amjmed.2009.04.022","journal-title":"Am J Med"},{"issue":"4","key":"10454_CR8","doi-asserted-by":"publisher","first-page":"e008113","DOI":"10.1161\/CIRCHEARTFAILURE.120.008113","volume":"14","author":"A Sinha","year":"2021","unstructured":"Sinha A, Ning H, Carnethon MR et al (2021) Race- and sex-specific population attributable fractions of incident heart failure: a population-based cohort study from the lifetime risk pooling project. Circ Heart Fail 14(4):e008113. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008113","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10454_CR9","doi-asserted-by":"publisher","first-page":"e003116","DOI":"10.1161\/CIRCHEARTFAILURE.115.003116","volume":"9","author":"JE Ho","year":"2016","unstructured":"Ho JE, Enserro D, Brouwers FP et al (2016) Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ Heart Fail 9(6):e003116. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.003116","journal-title":"Circ Heart Fail"},{"issue":"22","key":"10454_CR10","doi-asserted-by":"publisher","first-page":"e009599","DOI":"10.1161\/JAHA.118.009599","volume":"7","author":"M Fliotsos","year":"2018","unstructured":"Fliotsos M, Zhao D, Rao VN et al (2018) Body mass index from early-, Mid-, and older-adulthood and risk of heart failure and atherosclerotic cardiovascular disease: MESA. J Am Heart Assoc 7(22):e009599. https:\/\/doi.org\/10.1161\/JAHA.118.009599","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10454_CR11","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"8","key":"10454_CR12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","volume":"5","author":"NS Bassi","year":"2020","unstructured":"Bassi NS, Ziaeian B, Yancy CW, Fonarow GC (2020) Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol 5(8):948\u2013951. https:\/\/doi.org\/10.1001\/jamacardio.2020.0898","journal-title":"JAMA Cardiol"},{"key":"10454_CR13","doi-asserted-by":"publisher","unstructured":"Bozkurt B, Ahmad T, Alexander KM, et al (2013) Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America.\u00a0J Card Fail 29(10):1412\u20131451. https:\/\/doi.org\/10.1016\/j.cardfail.2023.07.006Huffman","DOI":"10.1016\/j.cardfail.2023.07.006Huffman"},{"issue":"14","key":"10454_CR14","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.jacc.2013.01.022","volume":"61","author":"MD Huffman","year":"2013","unstructured":"Huffman MD, Berry JD, Ning H et al (2013) Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 61(14):1510\u20131517. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10454_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa020245","volume":"347","author":"S Kenchaiah","year":"2002","unstructured":"Kenchaiah S, Evans JC, Levy D et al (2002) Obesity and the risk of heart failure. N Engl J Med 347(5):305\u2013313. https:\/\/doi.org\/10.1056\/NEJMoa020245","journal-title":"N Engl J Med"},{"issue":"19","key":"10454_CR16","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1161\/CIRCULATIONAHA.107.188965","volume":"117","author":"DD Schocken","year":"2008","unstructured":"Schocken DD, Benjamin EJ, Fonarow GC et al (2008) Prevention of heart failure: a scientific statement from the American Heart Association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group. Circulation 117(19):2544\u20132565. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.188965","journal-title":"Circulation"},{"key":"10454_CR17","doi-asserted-by":"publisher","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in N Engl J Med. 2008;18(4):4].\u00a0N Engl J Med 351(13):1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031","DOI":"10.1056\/NEJMoa041031"},{"key":"10454_CR18","doi-asserted-by":"publisher","unstructured":"Khan SS, Matsushita K, Sang Y, et al (2024) Development and Validation of the American Heart Association 's PREVENT Equations [published correction appears in Circulation. 2024 Mar 12;149(11):e956].\u00a0Circulation 149(6):430\u2013449. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067626","DOI":"10.1161\/CIRCULATIONAHA.123.067626"},{"issue":"24","key":"10454_CR19","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ et al (2023) Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-Kidney-Metabolic Health: a scientific statement from the American Heart Association. Circulation 148(24):1982\u20132004. https:\/\/doi.org\/10.1161\/CIR.0000000000001191","journal-title":"Circulation"},{"key":"10454_CR20","unstructured":"US Census Quick Facts. Available at:\u00a0https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045217. Accessed 22 Ap 2024"},{"issue":"14","key":"10454_CR21","doi-asserted-by":"publisher","first-page":"e011874","DOI":"10.1161\/JAHA.118.011874","volume":"8","author":"F Rodriguez","year":"2019","unstructured":"Rodriguez F, Chung S, Blum MR, Coulet A, Basu S, Palaniappan LP (2019) Atherosclerotic cardiovascular disease risk prediction in disaggregated Asian and hispanic subgroups using electronic health records. J Am Heart Assoc 8(14):e011874. https:\/\/doi.org\/10.1161\/JAHA.118.011874","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10454_CR22","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA et al (2019) 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task force on clinical practice guidelines. Circulation 140(11):e596\u2013e646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678","journal-title":"Circulation"},{"key":"10454_CR23","doi-asserted-by":"publisher","unstructured":"Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.\u00a0BMJ 354:i4482. Published 2016 Sep 6. https:\/\/doi.org\/10.1136\/bmj.i4482","DOI":"10.1136\/bmj.i4482"},{"issue":"14","key":"10454_CR24","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383(14):1305\u20131316. https:\/\/doi.org\/10.1056\/NEJMoa2019422","journal-title":"N Engl J Med"},{"issue":"5","key":"10454_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.mcna.2004.04.016","volume":"88","author":"S Kenchaiah","year":"2004","unstructured":"Kenchaiah S, Narula J, Vasan RS (2004) Risk factors for heart failure. Med Clin North Am 88(5):1145\u20131172. https:\/\/doi.org\/10.1016\/j.mcna.2004.04.016","journal-title":"Med Clin North Am"},{"key":"10454_CR26","doi-asserted-by":"publisher","unstructured":"Adler ED, Voors AA, Klein L, et al (2020) Improving risk prediction in heart failure using machine learning [published correction appears in Eur J Heart Fail. 2020 Dec;22(12):2399. https:\/\/doi.org\/10.1002\/ejhf.2072].\u00a0Eur J Heart Fail 22(1):139\u2013147. https:\/\/doi.org\/10.1002\/ejhf.1628","DOI":"10.1002\/ejhf.2072 10.1002\/ejhf.1628"},{"issue":"1","key":"10454_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"M Ledwidge","year":"2013","unstructured":"Ledwidge M, Gallagher J, Conlon C et al (2013) Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310(1):66\u201374. https:\/\/doi.org\/10.1001\/jama.2013.7588","journal-title":"JAMA"},{"issue":"5","key":"10454_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10741-020-09927-x","volume":"26","author":"I Lakhani","year":"2021","unstructured":"Lakhani I, Wong MV, Hung JKF et al (2021) Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev 26(5):1141\u20131150. https:\/\/doi.org\/10.1007\/s10741-020-09927-x","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10454_CR29","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B et al (2021) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u201cOMics\u201d in AGEing (HOMAGE) randomized clinical trial. Eur Heart J 42(6):684\u2013696. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa758","journal-title":"Eur Heart J"},{"issue":"9","key":"10454_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/archinternmed.2009.56","volume":"169","author":"EB Levitan","year":"2009","unstructured":"Levitan EB, Wolk A, Mittleman MA (2009) Consistency with the DASH diet and incidence of heart failure. Arch Intern Med 169(9):851\u2013857. https:\/\/doi.org\/10.1001\/archinternmed.2009.56","journal-title":"Arch Intern Med"},{"issue":"10","key":"10454_CR31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.amjcard.2009.06.061","volume":"104","author":"EB Levitan","year":"2009","unstructured":"Levitan EB, Wolk A, Mittleman MA (2009) Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am J Cardiol 104(10):1416\u20131420. https:\/\/doi.org\/10.1016\/j.amjcard.2009.06.061","journal-title":"Am J Cardiol"},{"issue":"3","key":"10454_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ejhf.481","volume":"18","author":"TG Tektonidis","year":"2016","unstructured":"Tektonidis TG, \u00c5kesson A, Gigante B, Wolk A, Larsson SC (2016) Adherence to a Mediterranean diet is associated with reduced risk of heart failure in men. Eur J Heart Fail 18(3):253\u2013259. https:\/\/doi.org\/10.1002\/ejhf.481","journal-title":"Eur J Heart Fail"},{"key":"10454_CR33","doi-asserted-by":"publisher","unstructured":"Lara KM, Levitan EB, Gutierrez OM, et al (2019) Dietary Patterns and Incident\u00a0Heart\u00a0Failure in U.S. Adults Without Known Coronary Disease.\u00a0J Am Coll Cardiol 73(16):2036\u20132045. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.067","DOI":"10.1016\/j.jacc.2019.01.067"},{"issue":"1","key":"10454_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCHEARTFAILURE.113.000529","volume":"7","author":"DR Young","year":"2014","unstructured":"Young DR, Reynolds K, Sidell M et al (2014) Effects of physical activity and sedentary time on the risk of heart failure. Circ Heart Fail 7(1):21\u201327. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000529","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10454_CR35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jchf.2015.02.009","volume":"3","author":"LC Del Gobbo","year":"2015","unstructured":"Del Gobbo LC, Kalantarian S, Imamura F et al (2015) Contribution of major lifestyle risk factors for incident heart failure in older adults: the cardiovascular health study. JACC Heart Fail 3(7):520\u2013528. https:\/\/doi.org\/10.1016\/j.jchf.2015.02.009","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10454_CR36","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1161\/CIRCHEARTFAILURE.111.962589","volume":"4","author":"Y Wang","year":"2011","unstructured":"Wang Y, Tuomilehto J, Jousilahti P et al (2011) Lifestyle factors in relation to heart failure among Finnish men and women. Circ Heart Fail 4(5):607\u2013612. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.962589","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10454_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.109.887893","volume":"121","author":"G Hu","year":"2010","unstructured":"Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J (2010) Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation 121(2):237\u2013244. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.887893","journal-title":"Circulation"},{"key":"10454_CR38","doi-asserted-by":"publisher","unstructured":"Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner MA, Lavretsky H, Perak AM, Sharma G, Rosamond W (2022) American Heart Association . life's essential 8: updating and enhancing the American Heart Association 's construct of cardiovascular health: a presidential advisory from the American Heart Association . Circulation 146(5):e18-e43. https:\/\/doi.org\/10.1161\/CIR.0000000000001078","DOI":"10.1161\/CIR.0000000000001078"},{"key":"10454_CR39","doi-asserted-by":"crossref","unstructured":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.\u00a0JAMA 1991;265(24):3255\u20133264.","DOI":"10.1001\/jama.265.24.3255"},{"key":"10454_CR40","doi-asserted-by":"publisher","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, et al (2015) A randomized trial of intensive versus standard blood-pressure control [published correction appears in N Engl J Med. 2017 Dec 21;377(25):2506].\u00a0N Engl J Med 373(22):2103\u20132116. https:\/\/doi.org\/10.1056\/NEJMoa1511939","DOI":"10.1056\/NEJMoa1511939"},{"key":"10454_CR41","doi-asserted-by":"publisher","unstructured":"Ettehad D, Emdin CA, Kiran A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387(10022):957\u2013967. https:\/\/doi.org\/10.1016\/S0140-6736(15)01225-8","DOI":"10.1016\/S0140-6736(15)01225-8"},{"issue":"16","key":"10454_CR42","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/hrt.2011.225482","volume":"97","author":"J Butler","year":"2011","unstructured":"Butler J, Kalogeropoulos AP, Georgiopoulou VV et al (2011) Systolic blood pressure and incident heart failure in the elderly. the cardiovascular health study and the health Ageing and Body Composition Study. Heart 97(16):1304\u20131311. https:\/\/doi.org\/10.1136\/hrt.2011.225482","journal-title":"Heart"},{"issue":"22","key":"10454_CR43","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"3","key":"10454_CR44","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ejhf.1419","volume":"21","author":"J Januzzi","year":"2019","unstructured":"Januzzi J, Ferreira JP, B\u00f6hm M et al (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. Eur J Heart Fail 21(3):386\u2013388. https:\/\/doi.org\/10.1002\/ejhf.1419","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10454_CR45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"7","key":"10454_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"24","key":"10454_CR47","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"issue":"2","key":"10454_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"issue":"12","key":"10454_CR49","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jacc.2018.01.047","volume":"71","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Vaduganathan M, Khan MS et al (2018) Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes. J Am Coll Cardiol 71(12):1379\u20131390. https:\/\/doi.org\/10.1016\/j.jacc.2018.01.047","journal-title":"J Am Coll Cardiol"},{"key":"10454_CR50","doi-asserted-by":"publisher","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published correction appears in Lancet. 2019 Jan 5;393(10166):30].\u00a0Lancet 393(10166):31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","DOI":"10.1016\/S0140-6736(18)32590-X"},{"issue":"4","key":"10454_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"19","key":"10454_CR52","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"6","key":"10454_CR53","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/dom.14997","volume":"25","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Saraiva F, Sharma A et al (2023) Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials. Diabetes Obes Metab 25(6):1495\u20131502. https:\/\/doi.org\/10.1111\/dom.14997","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10454_CR54","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"10454_CR55","unstructured":"Pratley RE (2024) Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease. Presented at: European Society of Cardiology Congress; August 30-September 2, London, England"},{"issue":"1","key":"10454_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10454_CR57","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500\u2013508. https:\/\/doi.org\/10.1001\/jama.2016.10260","journal-title":"JAMA"},{"key":"10454_CR58","doi-asserted-by":"publisher","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.\u00a0N Engl J Med. Published online May 24, 2024. https:\/\/doi.org\/10.1056\/NEJMoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"issue":"23","key":"10454_CR59","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"24","key":"10454_CR60","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"issue":"6","key":"10454_CR61","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R et al (2022) finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial. Circulation 145(6):437\u2013447. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057983","journal-title":"Circulation"},{"key":"10454_CR62","doi-asserted-by":"publisher","unstructured":"Kolkhof P, Hartmann E, Freyberger A, et al (2021) Effects of Finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage [published correction appears in Am J Nephrol 52(8):692].\u00a0Am J Nephrol. 2021;52(8):642\u2013652. https:\/\/doi.org\/10.1159\/000516213","DOI":"10.1159\/000516213"},{"key":"10454_CR63","doi-asserted-by":"publisher","unstructured":"Savarese G, Lindberg F, Christodorescu RM, et al (2024) Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. a survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice.\u00a0Eur J Heart Fail 26(6):1408\u20131418. https:\/\/doi.org\/10.1002\/ejhf.3214","DOI":"10.1002\/ejhf.3214"},{"key":"10454_CR64","doi-asserted-by":"publisher","unstructured":"Savarese G, Lindberg F, Cannata A, et al (2024) How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC.\u00a0Eur J Heart Fail 26(6):1278\u20131297. https:\/\/doi.org\/10.1002\/ejhf.3295","DOI":"10.1002\/ejhf.3295"},{"key":"10454_CR65","doi-asserted-by":"publisher","unstructured":"Hammond MM, Everitt IK, Khan SS (2022) New strategies and therapies for the prevention of heart failure in high-risk patients.\u00a0Clin Cardiol 45 Suppl 1(Suppl 1):S13-S25. https:\/\/doi.org\/10.1002\/clc.23839","DOI":"10.1002\/clc.23839"},{"issue":"7","key":"10454_CR66","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cardfail.2023.03.012","volume":"29","author":"J Zheng","year":"2023","unstructured":"Zheng J, Mednick T, Heidenreich PA, Sandhu AT (2023) Pharmacist- and nurse-led medical optimization in heart failure: a systematic review and meta-analysis. J Card Fail 29(7):1000\u20131013. https:\/\/doi.org\/10.1016\/j.cardfail.2023.03.012","journal-title":"J Card Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10454-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10454-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10454-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:09:26Z","timestamp":1734160166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10454-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["10454"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10454-2","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"9 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Greene has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association , Amgen, AstraZeneca, Boehinger Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, and Roche Diagnostics. Dr. Sandhu has received research support from National Institutes of Health, American Heart Association , Novartis Pharmaceuticals, and Repreive Cardiovascular and has served as a consultant for Lexicon Pharmaceuticals. Dr. Go has received research support from the National Heart, Lung and Blood Institute and the National Institute of Diabetes, Digestive and Kidney Diseases. Dr. Ambrosy has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute (K23HL150159), the American Heart Association (2nd Century Early Faculty Independence Award), The Permanente Medical Group, Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Amarin Pharma, Inc., Bayer, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis. Dr. Stephen J. Greene, Dr. Josephine Harrington, and Dr. Andrew P. Ambrosy are Editorial Board members of Heart Failure Reviews. All other authors report no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}